Q2 Earnings Estimate for Exelixis Issued By Leerink Partnrs

Exelixis, Inc. (NASDAQ:EXEL) – Equities research analysts at Leerink Partnrs increased their Q2 2025 earnings per share estimates for shares of Exelixis in a research report issued to clients and investors on Saturday, July 26th. Leerink Partnrs analyst A. Berens now forecasts that the biotechnology company will earn $0.63 per share for the quarter, up from their prior estimate of $0.61. The consensus estimate for Exelixis’ current full-year earnings is $2.04 per share. Leerink Partnrs also issued estimates for Exelixis’ Q3 2025 earnings at $0.68 EPS, FY2025 earnings at $2.61 EPS and FY2026 earnings at $2.95 EPS.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Monday, July 28th. The biotechnology company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.63 by $0.12. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. The firm had revenue of $568.26 million for the quarter, compared to analyst estimates of $574.36 million. During the same period in the previous year, the business earned $0.84 EPS. The company’s revenue was down 10.8% compared to the same quarter last year.

Several other equities research analysts have also issued reports on the stock. Royal Bank Of Canada lowered their price target on shares of Exelixis from $50.00 to $45.00 and set a “sector perform” rating on the stock in a research note on Tuesday. Morgan Stanley lowered their price target on shares of Exelixis from $48.00 to $46.00 and set an “overweight” rating on the stock in a research note on Tuesday. Stifel Nicolaus boosted their price objective on shares of Exelixis from $38.00 to $41.00 and gave the stock a “hold” rating in a research note on Tuesday. Jefferies Financial Group set a $50.00 price objective on shares of Exelixis and gave the stock a “buy” rating in a research note on Tuesday, June 24th. Finally, UBS Group lowered their price objective on shares of Exelixis from $43.00 to $38.00 and set a “neutral” rating on the stock in a research note on Wednesday. One research analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $44.44.

Exelixis Trading Down 0.2%

Shares of EXEL stock opened at $36.85 on Tuesday. Exelixis has a 1 year low of $23.13 and a 1 year high of $49.62. The firm’s fifty day moving average price is $43.17 and its two-hundred day moving average price is $38.88. The firm has a market capitalization of $9.92 billion, a P/E ratio of 17.72, a PEG ratio of 0.73 and a beta of 0.28.

Institutional Trading of Exelixis

A number of institutional investors have recently bought and sold shares of EXEL. Coppell Advisory Solutions LLC acquired a new position in shares of Exelixis in the 4th quarter valued at approximately $25,000. Hemington Wealth Management raised its position in shares of Exelixis by 211.3% in the 1st quarter. Hemington Wealth Management now owns 769 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 522 shares in the last quarter. Colonial Trust Co SC increased its position in Exelixis by 616.9% during the 4th quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 765 shares in the last quarter. Byrne Asset Management LLC increased its position in Exelixis by 129.0% during the 2nd quarter. Byrne Asset Management LLC now owns 710 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 400 shares in the last quarter. Finally, Family Legacy Financial Solutions LLC acquired a new position in Exelixis during the 2nd quarter worth approximately $33,000. Institutional investors own 85.27% of the company’s stock.

Insider Transactions at Exelixis

In other Exelixis news, Director Sue Gail Eckhardt sold 18,838 shares of the business’s stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $42.74, for a total value of $805,136.12. Following the completion of the sale, the director owned 21,380 shares of the company’s stock, valued at $913,781.20. The trade was a 46.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CMO Amy C. Peterson sold 72,776 shares of the business’s stock in a transaction dated Friday, May 16th. The shares were sold at an average price of $45.47, for a total transaction of $3,309,124.72. Following the completion of the sale, the chief marketing officer directly owned 465,393 shares of the company’s stock, valued at $21,161,419.71. This represents a 13.52% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 456,605 shares of company stock worth $20,966,005. Company insiders own 2.82% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.